Objective -Antiphospholipid antibody (aPL) specificity for aPL-related events was evaluated in systemic lupus erythematosus (SLE). Methods-A study was carried out on 105 patients affected with SLE comparing the prevalence of lupus anticoagulant (LA) and IgG and IgM anticardiolipin antibodies (aCL) between patients with and without features of antiphospholipid syndrome (APS). Antiphospholipid antibody profile was subsequently evaluated in the aPL positive patients with and without aPL-related events, thus excluding the patients with complications of APS possibly due to factors other than aPL.
specificity of aPL assays (54.4%). When studying the 60 aPL positive patients, LA was specific (91/3%) for the diagnosis of aPL-related thrombosis, whereas aCL were not specific, although IgG aCL mean levels were higher in patients with arterial thrombosis than in those without APS features. Conclusions-LA but not aCL positivity is a specific tool for the diagnosis of thrombotic complications due to various neuropsychiatric disorders such as transient ischaemic attacks (n = 1), chorea (n = 1), epilepsy (n = 8), amaurosis fugax (n = 2), migraine (n = 1), psychosis (n = 7), and acute organic syndrome (n = 2); two patients had more than one neurological feature. Nine (98-6%) had livedo reticularis. Sixteen patients (1 5 2/2%) presented more than one manifestation. Fifty seven patients (54-3%) did not show any of the disorders mentioned.
Frequency of aPL, LA, IgG and IgM aCL in SLE patients with and without aPL-related manifestations is reported in table 1. No difference in frequencies of pre-term delivery and pre-eclampsia between aPL positive and negative patients was found.
Frequency of LA, IgG and IgM aCL and mean IgG and IgM aCL levels in the 60 aPL positive patients with SLE, with and without clinical manifestations of APS, are shown in table 2 and the figure.
Discussion
The frequency of aCL in our patients was similar to that reported by other authors.6 7 9 13 ' The frequency of LA was lower than the average reported by Love et al,4
but similar to that found by some authors. 4 Both aCL and LA detection are influenced by differences in sensitivity and specificity of methods applied, 8 15 in the definition of the positive/negative cut off points8 and in patient selection criteria. 45 Our data (table 1) show that thrombosis was strongly associated with LA activity and, to a lesser extent, with IgG aCL positivity.
Neurological symptoms were related to IgG aCL and livedo reticularis to LA. Recurrent .0 49 fetal loss and thrombocytopenia did not correlate with IA or aCL positivity. Recurrent fetal loss was an uncommon feature in our patients probably because aspirin was used at low doses in risk pregnancies. Previously, no direct relationship with aPL, both in SLE and non-SLE patients, has been reported in thrombocytopenia. 4 No selected manifestations were significantly correlated with IgM aCL; this agrees with a previous report. ' In conclusion, LA is the most specific parameter for the diagnosis of thrombotic complications due to aPL in patients with SLE; both IgG and IgM aCL are not specific for aPL-related events. In addition, the measurement of IgG aCL level seems to be a valuable requirement before attributing clinical value to aCL positivity.
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